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Abstract 21 
Recent studies indicate that metabolic risk for cardiovascular disease is increased in postmenopausal 22 
women suffering from disturbances such as hot flushes. In order to evaluate whether this is true also 23 
in peri-menopausal women we performed an observational study on 590 peri-menopausal women of 24 
an outpatient center at a University Hospital. Each cardiovascular risk factor such as blood pressure, 25 
fasting glucose, fasting lipids and the ten year risk for cardiovascular disease was tested for its 26 
relation to climacteric complaints. The Greene’s climacteric scale, and its subscales were used to 27 
evaluate climacteric symptoms. Analyses were corrected for confounders derived by personal history 28 
and anthropometric measures.  When corrected for confounders the Greene’s score was a positive 29 
determinant of triglycerides (R2=0.249; p=0.0001), triglycerides/HDL-cholesterol (R2=0.316; 30 
p=0.0001), glucose (R
2
=0.101; p=0.0003), and the 10-year risk for cardiovascular disease, calculated 31 
by the Framingham formula (R
2
=0.081; p=0.0001). The Greene’s vasomotor sub-score was an 32 
independent determinant of LDL-cholesterol (R2=0.025; p=0.01), and LDL/HDL-cholesterol 33 
(R
2
=0.143;p=0.0001), while the Greene’s depression sub-score was a negative determinant of HDL-34 
cholesterol (R2=0.179; p=0.0001). The data indicate that also in peri-menopausal women, menopausal 35 
symptoms evaluated by a validated climacteric scale are associated with biochemical risk factors for 36 
atherosclerosis and cardiovascular disease.  37 
 38 
39 
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1. Introduction 40 
Recent studies indicate that postmenopausal women suffering from disturbances such as hot flushes 41 
may be at increased risk for cardiovascular disease. They have a higher BMI [1-3], higher blood 42 
pressure [4], increased aortic and artery calcification [5,6], reduced flow-mediated endothelium-43 
dependent vasodilatation [5,6] and a less favorable lipid profile [7]. At the moment it is unclear 44 
whether these relations do occur also in women in the peri-menopausal period. This is a period in 45 
which clinical disturbances and metabolic changes start to occur, as the consequence of ovarian 46 
endocrine modification [8-10]. In one study selectively performed in peri-menopausal women higher 47 
vasomotor symptoms were reported to be associated with higher levels of both atherogenic (LDL and 48 
triglycerides) and anti-atherogenic (HDL-) lipoproteins [11].  Hot flushes are associated with sleep 49 
and mood disturbances [12,13] and these disturbances increase in peri-menopausal women [14,15]. 50 
Accordingly, analyses evaluating the bulk of climacteric disturbances are probably more appropriate 51 
in determining the impact that these may exert on women’s health. Recently, we reported that in 52 
postmenopausal women the extent of menopausal disturbances as evaluated by the Greene 53 
climacteric scale, is related to endocrine and metabolic modifications possibly leading to an increased 54 
cardiovascular risk [16,17]. In this cross-sectional investigation we wanted to evaluate whether the 55 
same applies to women in the peri-menopausal period.  56 
57 
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 2. Methods 58 
Data of women attending the outpatient service for the menopause at our University Hospital in 59 
Modena were retrospectively retrieved from an electronic database. Symptomatic but also 60 
asymptomatic women that are interested in health prevention attend the service. Once entering in our 61 
center, each woman signs a consent form for the anonymous use of her personal data in research. The 62 
Institutional Review Board approved the anonymous extraction of the data of interest. Of the 4322 63 
consultations at the Center performed between May 2005 and December 2012, 525 were excluded 64 
because women were on hormonal therapy possibly interfering with items evaluated by the Greene 65 
climacteric scale (progestins, estrogens or estrogens plus progestins). Of the remaining 3797 66 
consultations, 920 were performed in postmenopausal women, 98 in the reproductive stages below -3 67 
(premenopause) of the STRAW classification (a well recognized although not wholly reliable method 68 
to assess different reproductive life stages) [18] and 79 had incomplete data. We used only the data of 69 
the entry visit and excluded the 2110 re-evaluations performed on the same subjects. Accordingly, 70 
analysis was performed on 590 peri-menopausal women, (reproductive stage -2 and -1 of the 71 
STRAW classification),. In these women FSH levels were higher than 30 IU/L and each woman had 72 
a period of amenorrhea <12 months.  73 
For each single woman we extracted data such as: age, age at menarche, history of hypertension 74 
(no/yes), diabetes (no/yes), smoking behavior (never, past, current), leisure activity (low, moderate, 75 
elevated), daily use of wine, beer (no/yes) or daily use of alcoholic beverages (no/yes), use of 76 
cholesterol-lowering medicine (no/yes), education level (primary, intermediate; higher; university), 77 
height (m), weight (kg), body mass index (BMI; Kg/m2), waist and hip girth, waist/hip ratio, systolic 78 
and diastolic blood pressure, fasting levels of glucose, LDL-cholesterol, HDL-cholesterol, 79 
triglycerides, LDL-cholesterol/HDL-cholesterol, and triglyceride/HDL-cholesterol. The Framingham 80 
risk score was calculated on the basis of risk factors for cardiovascular disease [19]. Weight (in 81 
kilograms) and height (in meters) reported in the records had been measured while women were 82 
wearing light clothes and no shoes. While in standing position, the girths of the women had been 83 
measured along the horizontal plane at the level of the natural waist (narrowest abdominal 84 
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 5 
circumference) and at the level of the hip (maximum extension of the buttocks). Office blood 85 
pressure had been measured after at least 10 minutes in a sitting position.  86 
Scores of validated Italian translation of self-administered questionnaires evaluating climacteric 87 
symptoms, anxiety and depressive symptoms were retrieved.  88 
The Greene’s climacteric scale was used to evaluate climacteric symptoms [20]. The Greene’s 89 
climacteric scale is composed of 21 items that evaluate vasomotor symptoms (two items), anxiety (six 90 
items), depression (five items), somatic symptoms (seven items), and sexuality (one item). For 91 
vasomotor symptoms the two questions were “do you suffer from hot flushes?” and “do you suffer 92 
from night sweat?”. All items have four options that range from not at all (0), a little (1), quite a bit 93 
(2), to extremely (3). The sum of items score is used to obtain the Greene climacteric scale score as a 94 
whole (range 0-63) or the scores of individual sub-scales for vasomotor symptoms (range, 0 to 6), 95 
anxiety (range, 0 to 18), depression ( ange, 0 to 15), somatic symptoms (range, 0 to 21) and sexuality 96 
(range, 0 to 3). Total score and subscales scores were used into the analysis, as numerical data. 97 
The Y-1 form of the State-Trait-Anxiety-Inventory (STAI) was used to further evaluate state of 98 
anxiety [21] and the Zung Scale (SDS) to further evaluate depression [22]. These scales are made up 99 
of 20 questions with 4 possible answers (score 1-4). Scores range from 20 (best) to 80 (worst).  100 
 101 
2.1. Assays 102 
Serum total cholesterol and triglycerides had been measured by enzymatic methods (Olympus 103 
AU400, Olympus Diagnostic GmbH, Lismeehan, Ireland), while HDL-cholesterol had been 104 
determined after precipitation with PEG 6000. The assay for cholesterol has a sensitivity of 5 mg/dL 105 
and a coefficient of variation (CV) of 3%. LDL-cholesterol was calculated accordingly to the 106 
Friedewald formula. Glucose had been determined by the glucose oxidase method. This assay has a 107 
CV of 1.4%. 108 
 109 
2.2. Statistical Analyses 110 
Statistical analyses were performed by the statistical Package Statview 5.0.1 for Apple Macintosh 111 
(SAS Institute Inc, Cary, NC, USA1998). 112 
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 6 
Each single biochemical cardiovascular risk factor such as HDL-cholesterol, LDL–cholesterol, 113 
triglycerides, glucose, LDL-cholesterol/HDL-cholesterol ratio the triglyceride/HDL-cholesterol ratio 114 
and the ten-year cardiovascular risk by Framingham risk score, as well as, systolic and diastolic blood 115 
pressure, was tested by multivariate analysis for its relation to each scale score (SDS, STAI, Greene’s 116 
and its subscores) along with age, age at menarche, presence of hypertension and diabetes, use of 117 
cholesterol-lowering medicine, leisure activity, smoking, level of education, BMI, waist/hip ratio. and 118 
FSH values. FSH was used as an indirect index of hypo-estrogenism, more strongly related than any 119 
other hormone to stages of menopausal transition and climacteric symptoms [16, 23]. Numerical data 120 
were entered into the analyses, as continuous data. Categorical data such as history of hypertension, 121 
of diabetes and use of cholesterol lowering medicine were entered into the analysis as single dummy 122 
variable, smoking behavior and leisure activity, as two dummy variables, and education as 3 dummy 123 
variables. For dummy variables the reference category was the absence of disease, medicine use, 124 
smoking, leisure activity or low education. Adjusted regression coefficients of independent 125 
determinants were obtained for each cardiovascular risk factor and the ten years cardiovascular risk. 126 
For all analyses a p value <0.05 was considered as significant. All results are expressed as mean + 127 
standard deviation (SD). 128 
129 
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3. Results 130 
Enrolled women had a mean age of 49.6+4.0 yr., BMI of 26.2+4.8 and a waist/hip ratio of 0.85+0.09. 131 
Ninety-one percent were married or in a long-term stable relationship, and 58.8% with a low grade of 132 
education. Among them, 43.5% engaged in leisure activities, 3.6% suffered from diagnosed 133 
hypertension and 0.5% suffered from diagnosed diabetes. Wine or beer were used daily by 43.5% of 134 
the women, while spirits were used by 1.65% of them.  The ten-year probability of cardiovascular 135 
disease was 2.25+5.3. The score of the Greene Climacteric scale was 27.3+13.3, of the STAI scale 136 
was 47.2+10.0, and of the SDS scale was 38.0+9.9 (Table 1). Women that were excluded for missing 137 
data did not differ from analyzed women in any of the parameters considered (data not shown). 138 
Neither STAI nor SDS scores were related independently to any biochemical or biophysical risk 139 
factor for cardiovascular disease. Data that were not independently related to any of the 140 
cardiovascular risk factor taken into consideration are not presented. 141 
Most cardiovascular risk factors were independently related to BMI and waist/hip ratio (Table 2). On 142 
the other hand, multiple regression analysis revealed that also the Greene’s Climacteric score and 143 
sometimes some of its sub-scores were independently related to most biochemical indexes of 144 
cardiovascular disease (Table 2). 145 
When corrected for confounders, along with BMI and waist/hip ratio the Greene’s score was a 146 
positive determinant of triglycerides (R2=0.249; p=0.0001), triglycerides/HDL-cholesterol (R2=0.316; 147 
p=0.0001), glucose (R2=0.101; p=0.0003), and the 10-year risk for cardiovascular disease calculated 148 
by the Framingham formula (R
2
=0.081; p=0.0001). The Greene’s vasomotor sub-score was the only 149 
parameter independently related to LDL-cholesterol (R2=0.025; p=0.01) and along with BMI and 150 
waist/hip ratio it was an independent determinant of LDL/HDL-cholesterol (R2=0.143;p=0.0001). 151 
The Greene’s depression sub-score was a negative determinant of HDL-cholesterol along with BMI 152 
and waist/hip ratio (R2=0.179; p=0.0001)(Table 2). 153 
The Greene’s score or its sub-scores were not determinants of blood pressure values. Positive 154 
determinants of systolic blood pressure were (R2=0.090; p=0.0001) age (β= 0.717; 95% confidence 155 
interval (CI) 0.409; 1.025), BMI (β = 0.598; 95% CI 0.335; 0.861), and waist/hip ratio (β =17.1; 95% 156 
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CI 2.5;31.8). Positive determinants of diastolic blood pressure were (R
2
=0.091; p=0.0001) age (β = 157 
0.377; 95%CI  0.169; 0.584) and BMI (β =0.564; 95% CI 0.387; 0.742). 158 
159 
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4. Discussion 160 
The data herein obtained confirm that also in peri-menopausal women the extent of climacteric 161 
complaints is associated with an enhanced risk of cardiovascular disease. In women across the 162 
menopause hot flushes are directly related to unfavorable metabolic modifications or sub-clinical 163 
indexes of cardiovascular disease [1-7]. Hot flushes are related to mood complaints [14,15], and 164 
along with them they characterize the bulk of menopausal disturbances. The Greene’s climacteric 165 
scale is a combination of sub-scales evaluating vasomotor complaints, mood, somatization, and 166 
sexuality. Accordingly, it summarizes the burden of climacteric disturbances. The present study was 167 
performed in a selected population of perimenopausal women, and it shows that the Greene’s scores 168 
are related to biochemical cardiovascular risk factors, to the Framingham calculation of the ten years 169 
risk of cardiovascular disease and to the triglyceride/HDL-cholesterol ratio. The latter is not included 170 
in the Framingham calculation, but it is still considered an independent risk factor for cardiovascular 171 
disease [24,25]. Similar data, were obtained, although inconsistently [26], in women mostly in 172 
postmenopause [7,16,17], by the evaluation of hot flushes alone.  173 
The association of climacteric symptoms with some cardiovascular risk factors may indicate a general 174 
vulnerability of selected women to gonadal steroid fluctuations of the perimenopause. On the other 175 
hand, it may also indicate a cause-effect relationship. It is difficult to hypothesize that climacteric 176 
symptoms are induced by metabolic abnormalities, but the opposite is possible. An increased 177 
catecholaminergic activity (27), and modification in calcitonin-related peptide [28] may represent 178 
mechanisms linking hot flushes with an increased cardiovascular risk. In postmenopausal women, we 179 
proposed that stressful menopausal symptoms increase cortisol production, and, as the consequence, 180 
insulin resistance and alterations of lipid metabolism [16,17]. Present data indicate that this may be 181 
true also in peri-menopausal women, where the Greene’s scores were related to biochemical 182 
modifications clustering in the metabolic syndrome such as decreased HDL, increased triglycerides, 183 
and increased glucose.  184 
Blood pressure was not related to the Greene’s climacteric score. Data on the association between hot 185 
flushes and blood pressure are mixed with some reporting an association [4,7] and others not [29]. It 186 
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is possible that for the limited number of the considered subjects, our study failed to find a significant 187 
association between climacteric symptoms and blood pressure values.  188 
This study has several limitations. The study was hospital-based and its results could not be applied to 189 
the general population. It has a cross-sectional design, which is, by the way, similar to many 190 
previously published studies [3-7, 16,17]. The study is based on subjective answers to questions with 191 
no objective evaluation. This is particularly true for the Greene’s vasomotor scale that was based on 192 
two questions testing patient’s bother associated with symptoms rather than frequency or severity of 193 
the symptoms. Nevertheless, the strength of this study is that it is not limited to hot flushes, a highly 194 
specific but single index of climacteric complaints, but instead it presents a more exhaustive 195 
evaluation of symptoms experienced by women across the menopausal transition. Furthermore, some 196 
confounding, such as the use of any hormone therapy were excluded.  197 
In conclusion, the present study supports the view that menopausal symptoms may be associated with 198 
certain biochemical risk factors for cardiovascular disease. The data indicate that these modifications 199 
start to occur very early, in the peri-menopause in association with the increase of menopausal 200 
complaints. Although, the correlations between the Greene Climacteric scale and the various 201 
outcomes account for only 10 to 30% of the variance, they indicate a metabolic change versus an un-202 
favorable condition that may possibly worsen with time. The data reinforce the view of proactively 203 
treating climacteric complaints as soon as they present. Likely, an early treatment contributes to 204 
prevent unfavorable metabolic modifications, but this possibility has yet to be fully explored.  205 
206 
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 1 
Table 1. Baseline characteristics (mean+SD) of the study population. 1 
 2 
Age (yrs.) 49.6+4.0  3 
BMI (kg/m2) 26.2+4.8 4 
Waist/Hip 0.85+0.09 5 
Blood Pressure systolic (mmHg) 128.4+19.8 6 
Blood Pressure diastolic (mmHg) 77.1+12.8 7 
Waist/Hip 0.85+0.09 8 
HDL-Cholesterol (mmol/l) 1.66+0.41 9 
LDL-Cholesterol (mmol/l) 3.89+1.36 10 
Triglycerides (mmol/l) 1.10+0.59 11 
Glucose (mmol/l) 5.09+0.82 12 
LDL-cholesterol/HDL-Cholesterol 2.25+1.04 13 
Triglycerides/HDL-Cholesterol 0.77+0.57 14 
Ten-Year probability of CVD* 2.25+5.3 15 
State-trait anxiety score (range 20-80) 47.2+10.0 16 
SDS score (range 20-80) 38.0+9.9 17 
Greene’s climacteric score (range 0-63) 27.3+13.1 18 
Greene’s anxiety sub-score (range 0-18) 6.6+3.9 19 
Greene’s depression sub-score (range 0-15) 5.9+3.7 20 
Greene’s somatic sub-score (range 0-21) 5.6+4.0 21 
Greene’s vasomotor sub-score (range 0-6) 2.6+2.1 22 
Greene’s sexuality sub-score (range 0-3) 1.3+1.1 23 
 24 
* calculated accordingly to the Framingham formula [20]. CVD=cardiovascular disease 25 
 26 
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 1 
Table 2. Adjusted regression coefficients by multiple regression analysis of independent 1 
determinants of each cardiovascular risk factor and of the ten-year risk for cardiovascular disease 2 
(CVD). 3 
Risk Factor              Determinant β coefficient 95% CI__________                 4 
 5 
HDL-Cholesterol (mmol/l)  6 
Greene depression  -0.029 -0.056; -0.084 7 
BMI   -0.025 -0.038;-0.013 8 
Waist/Hip  -0.787 -1.52; -0.002 9 
 10 
LDL-Cholesterol (mmol/l)  11 
 Greene vasomotor 0.012  0.001;0.025 12 
 13 
 14 
LDL-Cholesterol/HDL- Cholesterol  15 
 Greene vasomotor 0.063 0.002;0.0168 16 
 BMI 0.042 0.008;0.077 17 
 Waist/Hip 2.83 0.788;4.89 18 
 19 
 20 
Triglycerides (mmol/l) 21 
 Greene total 0.07  0.0004;0.013 22 
 BMI 0.039  0.0021; 0.058 23 
 Waist/Hip 2.54  1.46;3.61 24 
 25 
 26 
Triglycerides/HDL-Cholesterol  27 
 Greene total 0.06  0.022;0.095 28 
ΒΜΙ  0.032 0.016; 0.049 29 
 Waist/Hip  2.65 1.65;3.64 30 
 31 
 32 
Glucose (mmol/l)   33 
 Greene total  0.011  0.002;0.020 34 
 BMI 0.033  0.006;0.061 35 
 Waist/Hip 1.64  0.17;3.12 36 
  37 
 38 
Ten-Year Risk for CVD  39 
 Greene total 0.046  0.006;0.087 40 
 ΒΜΙ 0.157 0.046;0.267 41 
 Waist/Hip 13.98  7.16;20.8 42 
     43 
_____________________________________________________________________________44 
Regression models are adjusted for age, age at menarche, presence of hypertension, diabetes, use 45 
of cholesterol lowering medicine, smoking, leisure activity, level of education and FSH values.  46 
*The Ten-Year risk was calculated by the Framingham formula [19]. In this case the model was 47 
not adjusted for age and smoking, because these two parameters are necessary to calculate the 48 
ten-year risk.  49 
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